Psilocybin, Depression and Cancer

COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients.

Within one week of a single administration of COMP360 psilocybin therapy, 50% of participants achieved remission in depression symptoms, which was sustained for the eight week follow-up period.

Read more

Latest Research on Psychedelics and Depression

Here’s the latest on how there is a shift in psychiatry toward a new way of thinking about depression, its causes, and therapies.

The profession’s long embrace of the “monoamine hypothesis” — the idea that depression primarily results from abnormal levels of neurotransmitter chemicals in the brain and that drugs can restore the proper balance — is giving way to a more complex understanding and alternative treatments, from ketamine to psychedelics to magnetic stimulation.

Read more